Vitaccess
Vitaccess is a UK-based digital health company that designs and runs patient-centered real-world evidence studies and syndicated disease registries on its proprietary Vitaccess Real™ platform for pharmaceutical and biotechnology clients globally.
- Company typePrivate
- Founded2017
- HeadquartersOxford, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Vitaccess does
Vitaccess is a UK-headquartered (Oxford) digital healthcare company founded in 2017 that generates patient-centered real-world evidence (RWE) for pharmaceutical and biotechnology clients, with operational offices in London and Boston. The company operates its proprietary Vitaccess Real™ platform, which supports end-to-end RWE workflows including eCOA/ePRO, eCRF, eConsent, EMR integration, and AI-enabled real-time data dashboards, delivered under ISO 9001, ISO 27001, and GDPR-compliant security and quality frameworks. Its service catalogue spans observational studies, qualitative and quantitative research, registries (single- and multi-client syndicated, including MyRealWorld MG, Vitaccess Real MG/VRMG, and the Vitaccess Real CIDP Registry), health utilities and preference studies, patient-reported outcomes development and linguistic validation, analytics and data visualization, publication support, and patient and caregiver burden studies — covering 50+ deployed ePRO instruments and 100+ peer-reviewed publications across myasthenia gravis, Charcot-Marie-Tooth disease, melanoma, cystic fibrosis, and other rare and complex conditions.
Vitaccess monetizes primarily through professional-services contracts and registry subscriptions: study design and execution are priced on a custom project basis (multi-year contracts), and syndicated registries operate on a shared-funding subscription model that lets multiple sponsors access longitudinal datasets at lower per-sponsor cost than independent registries. Go-to-market is direct enterprise sales to pharma and biotech evidence-generation, medical affairs, and health economics/market access teams, supplemented by a global partnership with Envision Pharma Group (medical affairs communications), a rare-disease collaboration with RareiTi Inc., and an exclusive 2026 partnership with the Myasthenia Gravis Foundation of America on the VRMG registry. Marketing relies on thought leadership through peer-reviewed publications, conference participation (ISPOR, ISOQOL, AANEM), webinars, blog content, and LinkedIn — an approach calibrated to the scientifically rigorous buyer profile of biopharma evidence buyers rather than high-volume demand generation.
Vitaccess firmographics
Firmographics- Name
- Vitaccess
- Legal name
- Vitaccess Ltd
- Website
- https://vitaccess.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Vitaccess is a UK-based digital health company that designs and runs patient-centered real-world evidence studies and syndicated disease registries on its proprietary Vitaccess Real™ platform for pharmaceutical and biotechnology clients globally.
- Ownership category
- akta.pro rank
Vitaccess industry classification
Industry- Product category
- Real-World Evidence Research Services
- NAICS
- Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK)
- akta.pro secondary industries
- Real-World Evidence (RWE) & HEOR for Development (HLAIALAI), Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM), Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN)
Keywords
Where Vitaccess is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Vitaccess business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Registry Subscriptions: Subscription-based access to Vitaccess registry data including MyRealWorld MG and other syndicated registries. Subscribers benefit from shared funding, offering cost savings compared to independent registries.
- Real-World Study Services: End-to-end services for designing, running, and delivering global patient-centered research projects including observational studies, registries, qualitative research, health utility studies, and analytics.
- PRO/COA Instrument Services: Services for patient-reported outcome instruments including selection, licensing, translation, linguistic validation, and electronic migration (ePRO).
- Publication Support: Scientific writing and publication support services transforming complex data into peer-reviewed manuscripts, conference posters, and patient-facing materials.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Vitaccess product offering
Product offeringCore offering
Vitaccess designs and delivers patient-centered real-world evidence (RWE) studies for pharmaceutical and biotech companies, powered by its proprietary Vitaccess Real™ platform. The company operates across observational studies, registries, qualitative and quantitative research, health utilities, analytics, patient-reported outcomes (PRO/COA), translation and linguistic validation, and publication support to generate decision-grade evidence for regulatory, market access, and clinical development purposes.
Product overview
Vitaccess offers a comprehensive portfolio of real-world evidence services built around its proprietary Vitaccess Real™ platform. The platform provides end-to-end patient-centered RWE generation capabilities including eCOA/ePRO, eCRF, eConsent, EMR integration, and interactive data dashboards. Services include Observational Studies, Qualitative Research, Registries (such as MyRealWorld MG, VRMG, and CIDP Registry), Health Utilities & Preference Studies, Quantitative Research, Analytics & Data Visualization, Patient-reported Outcomes, Translation & Linguistic Validation, Publication Support, and Patient & Caregiver Burden Studies. The company specializes in rare disease and complex conditions, delivering evidence for regulatory submissions, market access, and clinical development.
Differentiator
Problem solved
Functional benefit
Brands
- Vitaccess Real™: Patient-centered RWE platform that captures patient, caregiver, and clinician data with intuitive, mobile and computer-friendly design. AI-enabled dashboards provide real-time insights for sponsors, while ISO-certified, GDPR-compliant security ensures participant data protection.
- MyRealWorld MG
- Vitaccess Real MG (VRMG) Registry
- Vitaccess Real CIDP Registry
Products and services
- Vitaccess Real™ Platform End-to-end patient-centered RWE platform that captures patient, caregiver, and clinician data through intuitive mobile and computer-friendly design, providing real-time insights via AI-enabled dashboards for sponsors.
- Observational Studies Designing and running prospective and retrospective observational studies that collect patient-reported and clinical data, powered through the Vitaccess Real™ platform.
- Qualitative Research Specialist interviews and debriefs that capture patient and caregiver experiences including concept elicitation, cognitive debriefing, and exit interviews.
- Registries Global registry programs capturing long-term, real-world patient-reported and clinical data with scientific precision, available as single or multi-client syndicated registries with subscription-based access.
- Health Utilities & Preference Studies Studies measuring how patients, caregivers, healthcare professionals and the public value treatment attributes and health outcomes, including vignette valuation and discrete choice experiments.
- Quantitative Research Expert elicitation (Delphi panels), cross-sectional surveys, longitudinal studies, and mixed-methods approaches using quantitative research methodologies.
- Analytics & Data Visualization Data science, biostatistics and econometrics with custom dashboards and real-time data presentation for study monitoring.
- Patient-reported Outcomes Selection, validation, translation, ePRO migration, and custom questionnaire development to capture meaningful patient insights for clinical outcome assessments.
- Translation & Linguistic Validation Regulatory-grade translation and linguistic validation of clinical outcome assessments using ISO 17100-qualified linguists, following FDA, EMA, and ISPOR best practices.
- Publication Support Medical writing and scientific communications including abstracts, posters, manuscripts and plain-language summaries for clinicians, regulators, and patients.
- Patient & Caregiver Burden Studies Studies capturing the physical, emotional, social, and financial impact of disease on patients and caregivers to quantify unmet need and inform value stories.
- MyRealWorld MG International observational longitudinal study designed to understand the impact of myasthenia gravis on patients' lives.
- Vitaccess Real MG (VRMG) Registry Decade-long patient registry designed to collect real-world evidence on myasthenia gravis, combining medical records with monthly patient-reported outcomes to support regulatory submissions, market access, and new therapy development.
- Vitaccess Real CIDP Registry First-of-its-kind international patient registry in chronic inflammatory demyelinating polyneuropathy (CIDP) linking clinical and patient-reported outcomes data.
Quantifiable outcome
- Over 90% participant compliance in real-world studies
- +4 more outcomes
Companies that use Vitaccess
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles2 records
Vitaccess technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature5 records
Vitaccess partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship and core.
- Myasthenia Gravis Foundation of America (MGFA)flagshipExclusive partnership making MGFA the official collaborator for the Vitaccess Real MG (VRMG) registry, creating one of the most comprehensive patient-centered evidence platforms in myasthenia gravis. The partnership integrates MGFA's 10+ years of legacy registry data with patient-reported outcomes and clinical data to generate decision-grade evidence supporting regulatory submissions, market access, and new therapy development. MGFA holds a seat on the VRMG Scientific Advisory Board.
- Envision Pharma GroupcoreGlobal partnership combining Envision's leadership in medical affairs communications with Vitaccess' award-winning capabilities in real-world evidence generation. The partnership powers evidence generation for the biopharmaceutical industry, integrating medical affairs expertise with RWE capabilities.
- RareiTi Inc.coreCollaboration offering unique services in real-world data to support biopharmaceutical companies in rare disease. RareiTi provides data-driven early access and clinical patient services, combined with Vitaccess' digital RWE research capabilities.
- Patient Advocacy Groups (60+ relationships)coreExtensive network of 60+ relationships with patient associations and key opinion leaders for patient recruitment, study co-design, and community engagement across global real-world studies.
Scale indicators8 records
Recent moves11 records
Expansion highlights6 records
Vitaccess competitors and assessment
Company assessmentBroad incumbents
- IQVIA: Largest global CRO and RWE provider with a dedicated Real World Evidence Solutions practice spanning observational research, HEOR and patient-reported outcomes. Competes head-on with Vitaccess on biopharma-sponsored RWE, registries and PRO studies, but at vastly greater scale and with bundled clinical offerings.
- Medidata Solutions (Dassault Systèmes): Leading eClinical platform provider (Rave EDC, eCOA/ePRO) used across clinical trials and increasingly RWE. Competes with Vitaccess Real™ at the technology layer for eCOA/ePRO, eConsent and data capture functionality within biopharma studies.
Direct peers
- ICON plc: Top-tier global CRO (post-PRA Health acquisition) with significant real-world evidence and HEOR capabilities. Directly competes for the same biopharma evidence-generation budgets, including in rare disease, with broader clinical operations alongside RWE.
- Parexel: Global CRO with established patient-centered RWE and HEOR services. Competes with Vitaccess on observational studies, registries and PRO-based evidence for biopharma customers across multiple therapeutic areas.
- Syneos Health: Biopharma solutions organization combining CRO services with commercial and real-world evidence offerings. Competes with Vitaccess on patient-centric RWE generation, including registries, observational research and PROs for biopharma sponsors.
- Evidera (PPD / Thermo Fisher Scientific): Pure-play RWE and HEOR research organization within Thermo Fisher's PPD clinical research business. Direct competitor on patient-reported outcomes, registries, health utilities and payer evidence — essentially a scaled-up version of Vitaccess's core services.
- Lumanity: RWE, HEOR and market access consulting firm serving biopharma customers. Competes with Vitaccess on evidence generation for regulatory, payer and market access use cases, with overlapping service lines in patient-centered research and value communications.
- Trinity Life Sciences: Life sciences strategic advisory with strong RWE, HEOR and patient-centered outcomes practices. Competes with Vitaccess on observational research, PRO strategy and evidence synthesis for biopharma brand, medical affairs and market access teams.
Emerging players
- Castor: Cloud eCRF and decentralized trial platform increasingly used for real-world and observational studies. Overlaps with Vitaccess Real™ on eCRF, eConsent and remote data capture, particularly for mid-market biopharma and academic sponsors.
- THREAD: Decentralized clinical trials and real-world evidence technology platform supporting eCOA/ePRO, eConsent and remote data capture. Competes with Vitaccess at the technology-enabled RWE and patient-centric study execution layer, particularly for hybrid and decentralized designs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Vitaccess social profiles
Digital presenceVitaccess compliance and trust
Trust signalCompliance4 records
Vitaccess financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vitaccess leadership team
Management profileNumber of profiles
Profiles11 records
Vitaccess funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vitaccess M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vitaccess
What does Vitaccess do?
Vitaccess designs and delivers patient-centered real-world evidence (RWE) studies for pharmaceutical and biotech companies, powered by its proprietary Vitaccess Real™ platform. The company operates across observational studies, registries, qualitative and quantitative research, health utilities, analytics, patient-reported outcomes (PRO/COA), translation and linguistic validation, and publication support to generate decision-grade evidence for regulatory, market access, and clinical development purposes.
Is Vitaccess a public or private company?
Vitaccess is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Vitaccess founded?
Vitaccess was founded in 2017. It employs 51 to 100 people.
Where is Vitaccess based?
Vitaccess is headquartered in Oxford, United Kingdom, in the Europe region.
How does Vitaccess make money?
Four revenue lines are on record. Registry Subscriptions are the primary driver. The others are real-World Study Services, PRO/COA Instrument Services and publication Support.
Who are Vitaccess's main competitors?
Broad incumbents on record are IQVIA and Medidata Solutions (Dassault Systèmes). Direct peers are ICON plc, Parexel, Syneos Health, Evidera (PPD / Thermo Fisher Scientific), Lumanity and Trinity Life Sciences. Emerging players are Castor and THREAD.
Does Vitaccess have an API?
No public API is recorded for Vitaccess.
What industry is Vitaccess in?
Vitaccess's product category is Real-World Evidence Research Services. Its primary akta.pro industry code is HLAGAAAK, Real-World Evidence (RWE), HEOR & Epidemiology CROs, with a secondary code of HLAIALAI, Real-World Evidence (RWE) & HEOR for Development. Its NAICS code is 5417 and its SIC code is 8731.